Clinical Trial Update: Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating erlotinib in combination with carboplatin for recurrent ovarian, fallopian tube, or primary peritoneal cancer completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: NCIC Clinical Trials Group | Conditions: Fallopian Tube Cancer, Ovarian Cancer | Phase 2 | Status: COMPLETED